Definition, botanical source, and scope
Albizia flower extracts are mixtures prepared from the dried inflorescences or flower buds of Albizia julibrissin Durazz., a member of the legume family, by solvent extraction followed by separation, concentration, and usually drying. Open inflorescences are commonly sold as Hehuanhua, whereas the buds may be called Hehuanmi. Developmental stage and the proportion of stalk material can affect composition, so the actual input should be stated. This entry does not cover albizia bark, leaves, seeds, essential oil, isolated quercitrin, or multi-ingredient formulas that happen to contain the flower. Bark and flowers are not interchangeable merely because they come from the same species; they are different medicinal parts with different dominant constituents and standards.
“Albizia flower extract” describes a product class, not a standardized formulation. A label that says only albizia, silk tree, hehuan, or yehe without a scientific name, plant part, and process does not establish that the material corresponds to pharmacopoeial Albiziae Flos. The currently accepted botanical spelling is Albizia with one z; Albizzia in older publications is often a historical spelling, but a spelling match alone must never be used to merge different species or plant parts. Traditional use of the herb, inclusion in a pharmacopoeia, and lawful sale of a finished food or supplement are separate questions. None by itself proves a clinical effect on sleep.
Starting material, extraction, and specification
Water, dilute ethanol, and high-concentration ethanol do not transfer flavonoid glycosides, phenolic acids, volatile compounds, and other constituents in the same proportions. Harvest stage, drying temperature, storage time, milling, extraction temperature, and duration can further alter the chemical fingerprint. Aroma mainly reflects a subset of volatile compounds and cannot replace identity or composition testing. Heating during concentration and prolonged storage may also reduce volatile material. A purified molecule, an ethyl-acetate fraction, or a high-ethanol laboratory extract is therefore not equivalent to a decoction, a defined standard decoction, or an ordinary spray-dried commercial powder.
A comparable specification should identify the species, bud or inflorescence input, extraction solvent, mass of starting herb, native extract mass, drug-to-extract ratio, carrier, and delivered amount per serving. A claim such as “10:1” has little meaning unless its calculation basis, extraction yield, and excipient fraction are disclosed, and the net mass of a powder is not necessarily the mass of native extract. Quercitrin, isoquercitrin, afzelin, or total flavonoids can help characterize a lot. A single marker, however, is neither a species-unique identity test nor a unit of sedative or sleep-promoting potency.
Human evidence and preclinical signals
At the time of this review, public searches did not identify a randomized controlled trial in people with insomnia that tested a clearly identified, specification-matched, single-ingredient albizia flower extract and reported recognized sleep outcomes. It is therefore unknown whether such an extract improves sleep-onset latency, nighttime wakefulness, total sleep time, sleep efficiency, next-day function, or insomnia severity compared with placebo. Reliable human dose-response, onset, and long-term benefit data are also unavailable. Studies of traditional formulas or combined treatments cannot isolate the effect of the flower extract, and evidence on albizia bark cannot be transferred to the flower.
The frequently cited signals are preclinical. Quercitrin and isoquercitrin isolated from the flowers prolonged pentobarbital-induced sleeping time in mice. That is an animal drug-interaction endpoint, not evidence of improved natural sleep, treatment of chronic insomnia, or better next-day function in humans. A study of an albizia preparation in sleep-deprived fruit flies assessed memory, not human sleep architecture. Cell assays, network pharmacology, molecular docking, and antioxidant findings may generate hypotheses but cannot establish that neurotransmitters are clinically regulated or that depression, anxiety, or deep sleep is improved. Comparative reviews likewise call for more pharmacokinetic, toxicological, quality, and clinical research.
Authentication and batch quality
Before extraction, identity can be supported by inflorescence or bud morphology, microscopy, chromatographic comparison, and an appropriate botanical method when needed. Research on confused Chinese materia medica notes that the shared vernacular name Yehehua can lead to the flower of Magnolia coco being substituted for Albiziae Flos. A defensible supply chain therefore uses the Latin binomial, medicinal part, supplier documentation, and retained samples rather than color, fragrance, or a vernacular name alone. Extraction removes morphology, and intensive processing may degrade DNA, so pre-extraction authentication must be connected to finished-product multicomponent fingerprints, mass balance, and traceable manufacturing records.
Batch release should also address moisture and microbial control, pesticide residues, toxic elements, mycotoxins, residual solvents, and undeclared ingredients, with methods, batch numbers, sampling dates, and laboratories tied to the product actually sold. Pharmacopoeial herbs and defined formula granules may have quercitrin and characteristic-fingerprint criteria, but their limits and methods apply to the named regulated article. An arbitrary extract does not become equivalent because it is called “pharmacopoeial grade” or contains detectable quercitrin. Input-output mass balance and trend review help detect excessive carrier, wrong plant part, substitution, degradation, or lot drift.
Product selection and outcome review
First determine whether the item is a single flower extract, a medicinal formula granule, a multi-ingredient supplement, or a flavored beverage. Then check the market for which it is labeled, the responsible company, complete ingredient list, lot-specific testing, and warnings. Value comparisons should use native extract delivered per serving, a verifiable extraction ratio, and expected duration of use rather than capsule count, total powder mass, or a “high potency” phrase. If melatonin, other sedating herbs, alcohol, or any ingredient that may alter alertness is present, a perceived change cannot be attributed to albizia flower.
Personal use cannot repair the clinical evidence gap, but a structured review can reduce misattribution. Before starting, record one to two weeks of bedtime, wake time, estimated sleep onset, wakefulness during the night, total sleep, naps, caffeine and alcohol, next-day sleepiness, and important symptoms. Keep light exposure, schedule, and other interventions reasonably stable, and change only one variable at a time. Define an early review date and stop criteria in advance rather than escalating after one or two good nights. Stop and reassess if there is no stable, meaningful benefit or if morning impairment, dizziness, gastrointestinal symptoms, rash, or paradoxical activation appears.
Safety limits and reasons for referral
Albizia flower extracts do not have adequate long-term human safety data. A history of traditional use cannot be converted into established safety during pregnancy or breastfeeding, in children or older adults, or in people with impaired liver or kidney function. Concentration can also produce exposures and constituent proportions unlike those from a small amount of decocted herb. Until an individual response is known, a first use should not be followed by driving, operating machinery, or other tasks requiring sustained alertness. Evidence on interactions with prescription hypnotics, anxiolytics, antidepressants, antihistamines, alcohol, and other sleep products is insufficient; a physician or pharmacist should review combinations, and an extract should not be stacked with or substituted for treatment without guidance.
People who are pregnant or breastfeeding, children, those preparing for surgery, people with serious chronic disease or polypharmacy, and those with previous plant-product allergy should not make the decision from marketing material alone. Breathing difficulty, swelling of the face or lips, widespread rash, or a marked change in consciousness or behavior requires immediate discontinuation and prompt care. Persistent insomnia with daytime impairment, witnessed breathing pauses, unusual daytime sleepiness, restless legs, manic symptoms, worsening depression, or thoughts of self-harm warrants professional assessment. Multicomponent cognitive behavioral therapy for insomnia is a leading first-line treatment for chronic insomnia; an extract is not a substitute for diagnosis or evidence-based care.
Regulation, supply chain, and evidence communication
Listing of Albiziae Flos in a pharmacopoeia or traditional-medicine system does not automatically authorize it as an ordinary food, dietary supplement, or cross-border ingredient in every jurisdiction. Manufacturers and sellers must determine ingredient eligibility, product category, dosage and warning requirements, manufacturing controls, labeling, and claim rules in the destination market. A standard and conversion factor written for a particular Chinese medicine formula granule cannot be repurposed as an endorsement of an ordinary retail extract. Traditional-use language, structure or function claims, and authorization to treat disease must remain distinct.
An auditable chain begins with species and harvested part and records origin, developmental stage, drying, transport, storage, extraction lot, solvent, carrier, release testing, stability, complaints, and recalls. Research summaries should disclose species, plant part, preparation, model, and endpoint instead of compressing mouse drug-induced sleeping time, fruit-fly memory, cell pathways, or a multi-herb observation into “clinically proven sleep support.” If finished-product human trials emerge, their preregistration, comparator, blinding, sample size, objective and subjective outcomes, adverse-event collection, and conflicts of interest will still matter more than statistical significance or a promotional abstract alone.